Compare FSLY & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSLY | NVCR |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2019 | 2015 |
| Metric | FSLY | NVCR |
|---|---|---|
| Price | $20.25 | $13.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $13.00 | ★ $28.08 |
| AVG Volume (30 Days) | ★ 18.6M | 2.7M |
| Earning Date | 05-13-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.19 | 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | $624,018,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $15.51 | $7.72 |
| Revenue Next Year | $11.32 | $6.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.78 | 8.28 |
| 52 Week Low | $4.65 | $9.82 |
| 52 Week High | $21.75 | $21.55 |
| Indicator | FSLY | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 70.22 | 52.62 |
| Support Level | $7.43 | $12.66 |
| Resistance Level | $20.27 | $14.13 |
| Average True Range (ATR) | 1.82 | 0.99 |
| MACD | 0.17 | 0.22 |
| Stochastic Oscillator | 70.22 | 49.90 |
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focus on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly is in far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated nearly three fourths of its revenue in the United States in 2024.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.